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Loss of the transcription factor Ikaros is correlated
with Notch receptor activation in T cell acute lympho-
blastic leukemia (T-ALL). However, the mechanism
remains unknown.We identified promoters in Notch1
that drove the expression of Notch1 proteins in the
absence of a ligand. Ikaros bound to both canonical
and alternative Notch1 promoters and its loss
increased permissive chromatin, facilitating recruit-
ment of transcription regulators. At early stages of
leukemogenesis, increased basal expression from
the canonical and 50-alternative promoters initiated
a feedback loop, augmenting Notch1 signaling.
Ikaros also repressed intragenic promoters for
ligand-independent Notch1 proteins that are cryptic
in wild-type cells, poised in preleukemic cells, and
active in leukemic cells. Only ligand-independent
Notch1 isoforms were required for Ikaros-mediated
leukemogenesis. Notch1 alternative-promoter usage
was observed during T cell development and T-ALL
progression. Thus, a network of epigenetic and tran-
scriptional regulators controls conventional and
unconventional Notch signaling during normal devel-
opment and leukemogenesis.
INTRODUCTION
Regulatory factors that control normal development are
frequently implicated in neoplastic transformation. Ikaros,
a zinc finger DNA binding protein and a key regulator of lympho-
poiesis, is a prime example (Georgopoulos, 2009; Mullighan and
Downing, 2008). In the hematopoietic stem cell (HSC) compart-
ment, Ikaros is required for transcriptional priming of a lymphoidIgene expression program, enabling lymphoid differentiation to
the most primitive of hematopoietic progenitors (Ng et al.,
2009; Yoshida et al., 2010). Normal outcome of T cell develop-
ment also depends on Ikaros activity. Loss of Ikaros accelerates
transition through the b-selection checkpoint, causing an aber-
rant accumulation of T cell receptor (TCR)+ CD4+CD8+ ‘‘double
positive’’ (DP) thymocytes that rapidly transit to a leukemic state
(Winandy et al., 1999; Winandy et al., 1995). These phenotypes
implicate Ikaros as a regulator of signaling pathways and their
cellular outcome during T cell differentiation. Consistently, aber-
rant activation of Notch signaling occurs in Ikaros-deficient T cell
leukemias, implicating Ikaros as a negative regulator of this
pathway during T cell development and leukemogenesis (Chari
and Winandy, 2008; Dumortier et al., 2006; Kleinmann et al.,
2008; Mantha et al., 2007).
Notch signaling is another key determinant of lymphopoiesis.
The Notch receptors (Notch1–Notch4) are single-pass
membrane molecules that are cleaved by furin-like convertase
(S1) within the Golgi secretory pathway and presented as an in-
tramolecular heterodimer on the cell surface (Bray, 2006).
Receptor engagement by a ligand presented by a neighboring
cell exposes an extracellular ADAM metalloproteinase cleavage
site (S2) and a g-secretase cleavage site (S3) in the transmem-
brane region, releasing the Notch intracellular domain (ICN),
and transmitting Notch signaling into the nucleus (De Strooper
et al., 1999). ICN associates with a DNA-binding complex
founded on the mammalian homolog of the recombining binding
protein suppressor of hairless (RBP-Jk, also known as CBF1)
(Fortini and Artavanis-Tsakonas, 1994), which helps recruit the
MAML coactivators to RBP-Jk binding sites (Nam et al., 2006;
Wilson and Kovall, 2006). These events consolidate activation
of gene expression programs promoting survival and cell
growth, which when deregulated lead to leukemic transforma-
tion (Palomero et al., 2006; Weng et al., 2006). Notch signaling
in lymphoid progenitors (from early thymic precursor [ETP]
through ‘‘double negative’’ 2 [DN2] stage) controls the choice
between B, myeloid, and T cell fates (Radtke et al., 1999;mmunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc. 685
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cooperates with pre-TCR signaling to expand thymocyte
numbers undergoing b-selection (Ciofani and Zu´n˜iga-Pflu¨cker,
2005; Garbe et al., 2006; Tan et al., 2005). Although Notch1
expression is maintained in DP thymocytes, Notch signaling is
blocked at this stage. Signaling resumes in peripheral T cells,
in which it controls the choice between effector cell fates (Amsen
et al., 2009). More than 50% of T-ALL (T-lineage acute lympho-
blastic leukemia) have Notch1-activating mutations in the heter-
odimerization and C-terminal PEST domains (Weng et al., 2004).
Although the connection between Ikaros loss of function and
Notch activation is well established in mouse T-ALL, it remains
unclear whether this interaction is direct or indirect. Loss of
Ikaros may provide aberrant survival properties to differentiating
thymocytes, predisposing them to further selection for activating
Notch mutations and a malignant phenotype. Here, we
described the use of alternative promoters within the Notch1
locus, one of which is upstream of the canonical promoter and
a second downstream within an intragenic region encoding
transmembrane domains. These alternative promoters gener-
ated transcripts supporting a ligand-independent phase in
Notch1 signaling and are active during T cell development and
leukemogenesis. We showed that Ikaros directly regulated the
epigenetic state and transcriptional output of canonical and
alternative Notch1 promoters. Deregulation of this epigenetic
process during T cell development caused aberrant activation
of Notch1 signaling and rapid development of T-ALL.
RESULTS
Effects of Combined Deletion of Ikaros and Notch1
on T Cell Development
To evaluate the role of Ikaros in Notch-mediated transcriptional
responses, we combined either of two Ikaros mutant mouse
genetic models (Ikaros null [Ikzf1/] or Ikaros dominant negative
[Ikzf1DN/+]) with a conditional inactivation model for Notch1 that
deletes a 3.7kb region encompassing the Notch1 promoter
and exon1 (Georgopoulos et al., 1994; Radtke et al., 1999;
Wang et al., 1996). Thymic Notch1 deletion with Lck Cre
(Figure 1, Notch1fl/fl Lck Cre; Notch1/), which deletes from
DN3 (Lee et al., 2001), or with CD2 Cre (data not shown), which
deletes from ETP (de Boer et al., 2003), gave similar results.
T cell development was evaluated in young (3–4 weeks) Notch1
and Ikaros double-deficient (Notch1/Ikzf1/) and single-defi-
cient mice. Hallmarks of Ikaros loss of function in the thymus
are a facilitation of the DN3 to DN4 transition and an increase in
CD4 SP thymocytes (Winandy et al., 1999), whereas hallmarks
of Notch1 loss of function are a partial block at the DN2-4 with
accumulation of a DN2-3 intermediate (CD25hi), a decrease in
DP and an increase in SP thymocytes (Figure 1A) (Radtke et al.,
1999). In the youngNotch1/Ikzf1/mice, a release of the previ-
ously described Notch1-loss-of-function mediated DN2-3 block
(5.8% versus 14.4%), a relative increase in DP (72%
Notch1/Ikzf1/ versus 58% Notch1/ or 59% Ikzf1/) and
decrease in CD4 SP T cells (17% Notch1/Ikzf1/ versus 32%
Ikzf1/) compared to single deficient mice were observed
(Figure 1A). Notch1 deletion was detected in most of thymocytes
in mutant mice (Figure 1B). As in the Notch1/ or Ikzf1/,
a decrease in thymic cellularity was detected in the686 Immunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc.Notch1/Ikzf1/ mice relative to WT (Figure 1C). Notably,
a reduction in CD8 SP was seen in the Notch1/Ikzf1/ thymus
with almost all remaining cells displaying an immature ISP
phenotype (TCR–/int/HSAhi, Figure 1D) suggesting that Notch1
and Ikaros may cooperate in the development of the CD8 SP
lineage (Robey, 1999).
Notch1 Signaling in Ikaros-Mediated Leukemogenesis
Unexpectedly, from 6 weeks Notch1/Ikzf1/ mice began
to develop T cell leukemia at a faster rate than Ikzf1/ mice
(Figure 2A). This effect of Notch1 deletion was observed in all
Ikaros mutant genetic backgrounds (Figure 2A and data not
shown) and was especially prominent in mice heterozygous for
the Ikaros null mutation, which usually undergo normal T cell
development and develop disease at low frequency at advanced
age (>6 months): the Notch1/Ikzf1+/ mutants developed
leukemia at high penetrance within 2–5 months. Deletion of
one Notch1 allele was sufficient to accelerate leukemogenesis,
albeit at an intermediate rate compared with double deletion,
indicating a gain of function provided by the mutant locus (data
not shown). Unlike Notch1/Ikzf1/ or Ikzf1/ mice,
Notch1/ mice never developed disease, indicating that the
initiating event for transformation is Ikaros dependent. Acceler-
ated tumor formation in Ikzf1+/ and Ikzf1/ indicates the pres-
ence of an Ikaros-independent component, possibly related to
deletion of a second negative regulator operating from the
Notch1 promoter.
The leukemic clones arising in the Ikaros-Notch1 compound
mutants (Notch1/Ikzf1+/, Notch1/Ikzf1/, and Notch1/
Ikzf1DN/+) had a prevailing DP-transitional TCRint phenotype
similar to that described in Ikzf1/ mice (Figure 2B and data
not shown). Genomic PCR and RT-PCR analysis of these clones
confirmed deletion of the Notch1 canonical exon1 (E1c) (Figures
2C and 2D) and revealed thatHes1 and Il2ra (encoding CD25) are
also induced suggesting activation of Notch signaling (Figures
2B and 2D). Notch1/Ikzf1/ thymocytes in the preleukemic
state (3–4 weeks, polyclonal) and leukemic state (>8 weeks,
monoclonal) were further evaluated for Notch1 protein expres-
sion. Notch1/ and preleukemic Notch1/Ikzf1+/ thymocytes
showed a similar reduction in S1-cleaved Notch1 (120 kDa)
below WT amounts (Figure 2E, lanes 2 and 4). In contrast,
Notch1/Ikzf1/ or Notch1/Ikzf1DN/+ leukemic clones ex-
pressed large amounts of short protein isoforms (<120 kDa)
not detected in WT or in preleukemic Notch1/Ikzf1+/ thymo-
cytes (Figure 2E, lanes 6, 7, and 9). One of these isoforms was
recognized by an antibody to ICN (Figure 2E; Val1744, lane 9).
Thus, alternative promoters supporting Notch signaling are acti-
vated at the mutant Notch1 locus during loss-of-Ikaros-medi-
ated leukemogenesis.
The relevance of alternative Notch1 isoforms to the leukemic
phenotype of Notch1/Ikzf1+/ clones was investigated.
Notch1/Ikzf1+/ leukemic clones lacking the canonical Notch1
isoform but expressing high amounts of alternative isoforms
(Figures 2C–2E, lanes 6, 7, and 9) were monitored for their ability
to grow in the presence of g-secretase inhibitors (GSIs).
Reduced proliferation in these clones indicated dependence
on the alternative Notch1 isoforms that are also cleaved at S3,
such as the canonical protein (Figures 2F–2H). In contrast, an
independently derived Ikzf1DN/+ clone failed to respond to GSI,
Figure 1. Combined Effects of Notch1 and Ikaros
Deletion on T Cell Development
(A) Thymocyte profiles of 3-week-old wild-type (WT),
Ikzf1/, Notch1/, and Notch1/Ikzf1/ littermates.
The upper panel shows CD4 and CD8 staining, the middle
the DN1 to DN4 staining of double negative (CD4–, CD8–
and Thy1.2–) thymocytes for CD44 and CD25. The lower
panel shows expression of TCRb and CD5 in total thymo-
cytes. Numbers indicate the percentage of cells in each
subset. Red gate shows the DN2-DN3 intermediate accu-
mulating in the Notch1/ thymus.
(B) Genomic PCR analysis of thymic deletion of theNotch1
locus by LckCre.
(C) Thymic cellularities in <1.5-month-old mice (n > 5).
Standard deviations (SD) are shown as error bars.
(D) CD8+ SP cells shown in (A) were further evaluated for
TCRb and HSA expression.
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(Figures 2F–2H).
We next combined Ikzf1/ or Ikzf1DN/+ mutants with a condi-
tional inactivating mutation in Rbpjfl/fl CD2 Cre (Rbpj/), the
nuclear effector of Notch signaling (Tanigaki et al., 2004). A
marked decrease in thymocyte cellularity and survival was
observed in Rbpj/Ikzf1DN/+ or Rbpj/Ikzf1/ mice (3–
21 weeks) (Figure 2I). Surviving Rbpj/Ikzf1/ thymocytes
had a predominant CD4+CD8neg-int TCRint-hi profile, similar to
Ikzf1/ (Figure 2J). However, unlike Ikzf1/, Rbpj/Ikzf1/
thymocytes monitored from 3–32 weeks were unable to expand
(Figure S1 available online). Rbpj/Ikzf1DN/+ mice did not
develop detectable lymphoma even after 32 weeks, a time byImmunity 33, 685–which most Ikzf1DN/+ mutant mice had suc-
cumbed to disease (Figure 2K and data not
shown for Ikzf1/). In the one case in which
an aberrant population was observed, the ex-
panding cells carried a wild-type Rbpj allele
(Figure 2K and data not shown). These genetic
studies indicate that Notch signaling is required
for the transition of Ikaros-deficient thymocytes
to a leukemic state and reveal the existence of
alternative promoters in the Notch1 locus that
generate signaling-competent Notch proteins
that are actively repressed by Ikaros.
Mapping of Alternative Notch1
Transcription Start Sites
Notch1 alternative promoters and transcription
start sites (TSSs) were evaluated by RNA anal-
ysis and 50 RACE of polyA+ RNA from leukemic
clones arising in the Notcht1/Ikzf1+/ and
other genetic backgrounds (Figure 3). Notch1
transcripts (9.5 kb) containing exons 3–6
(Figure 3A and Figure S2A) were detected in
WT thymocytes (85% DP) and in Notcht1/
Ikzf1+/, Notcht1+/Ikzf1+/, and Notcht1/
Ikzf1DN/+ leukemic clones (Figure 3B and Fig-
ure S2B; data not shown). 50 RACE from exon 3
revealed splicing to exon 1a, which is 13 kb up-
stream of exon 1 (Figure 3A) (Tsuji et al., 2003).
Transcripts (9.5 kB) containing E1a-E3 (E1a-
E3 through E34) were detected in leukemic clones but not WT
DP thymocytes (Figure 3B, E1a). RT-PCRandsequencing of E1a-
E3 transcripts revealed differential use of a second coding exon
downstream of exon1a, previously described as exon 1b (Tsuji
et al., 2003) (Figures 2D and 3A and Figure S2C). Analysis down-
stream of exon 24 (i.e., E25, E26, E28-31, and 34b), revealed four
additional transcripts ranging in size from 3.5–5.5 kb (Figures 3B
and 3C and Figures S2A and S2B). The four major short Notch1
transcripts arise from two intragenic TSSs, one in exon 25 and
a second in either intron 26 or 27 (Figure 3 and Figures S2A and
S2B), and two alternative polyA+ sites within exon 34 (Tsuji
et al., 2003). 50 RACE from exon 34 verified intragenic promoter
usageat exon 25 anddownstream intronic sites (data not shown).698, November 24, 2010 ª2010 Elsevier Inc. 687
Figure 2. The Role of Notch Signaling in Loss-of-Ikaros-Mediated Leukemogenesis
(A) Kaplan-Meier survival plot for mice with different Notch1 and Ikzf1mutations. All WT (n = 24) or Notch1/ (n = 15) mice remained healthy during observation
(6 months). Ikzf1+/ mice were also generally healthy (36/38). Eleven out of the twelve Notch1/Ikzf1+/ mice died of leukemia. Of the 12 Ikzf1/ mice, 1
survived, 2 died of anemia, and the rest died of leukemia. All Notch1/Ikzf1/ (n = 5) mice died during the first 2 months of study.
(B) Thymocyte profiles of WT and two representative diseased Notch1/Ikzf1+/ mice, as described in Figure 1A.
(C) Genomic PCR of leukemic clones deleted of the Notch1 canonical promoter and exon 1.
(D) Semiquantitative RT-PCR of E1c frommRNAs isolated from Notch1/Ikzf1+/ leukemic cells. Expression of E1a, Hes1, and Actb (control) was also detected
in these cells.
(E) Immunoblot analysis of whole-thymocyte extracts at different stages of disease development with a Notch1 C-terminal (C-term) and Ikaros (Ik) antibodies. The
right panel shows analysis of WT, pre-leukemic Ikzf1DN/+, and leukemic Notch1/Ikzf1+/ thymocytes with antibodies to Notch1 C terminus and also to ICN
(Val1744).
(F) Notch1/Ikzf1+/ cell lines (1537 and 1218) were treated with g-secretase inhibitors (GSIs) and the growth was measured (See Experimental Procedures).
Values of absorbance are represented as mean of triplicates from one representative experiment. The growth of an Ikzf1DN/+ (1891) GSI-resistant leukemic clone
is also shown. SDs are shown as error bars.
(G) Immunoblot analysis of cell-line extracts (as in E).
(H) Expression of alternative Notch1 transcripts.
(I) Thymic cellularities of single and combined Ikzf1 and Rbpj mutants at <2 months of age (n > 5). SDs are shown as error bars.
(J) Thymocyte profiles of WT, Ikzf1/ and Rbpj/Ikzf1/.
(K) Frequency of leukemic transformation (pink versus green) in single and combined KOmice. All experiments were repeated at least three times, but those of (F)-
(H), which were done twice.
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in leukemic clones that arise in Ikaros mutants with an intact
Notch1 promoter-exon 1 region. Alternative and canonical688 Immunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc.Notch1 transcripts were detected in most Ikaros mutant
leukemic clones (Figure 3C and Figures S2B and S2C). Activa-
tion of alternative Notch1 TSS, either upstream of the canonical
Figure 3. Mapping of Alternative TSS at theNotch1
Locus
(A) Promoter utilization at the Notch1 locus is shown.
Green, black, and red arrows demarcate the respective
50 alternative, canonical and intragenic TSSs described in
the text. cDNA probes are shown underneath relevant
regions. Open rectangles depict canonical exons, a red
rectangle depicts the alternative E1a, and a black rect-
angle depicts the alternative E1b. Two alternative polyade-
nylation sites in E34 are depicted by orange or green stars.
(B and C) Expression of Notch1 transcripts and ICN in WT
and leukemic cells derived from DKOs and Ikzf1DN/+
mutant mice. PolyA+ RNA and protein extracts were
analyzed by probe hybridization (upper panels) and immu-
noblots (lower panel). For monitoring Notch activation, the
a-Val1744 Ab was used. Transcripts with distinct polyA
sites are color-coded as in (A). All experiments were
repeated at least three times.
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strongly with loss of Ikaros and activation of Notch1 ICN and is
independent of deletion of the canonical Notch1 promoter
(Figures 3B and 3C and Figures S2B and S2C).
We also examined whether the effect of Ikaros on alternative
promoter use was specific for Notch1 or also manifested with
other Notch family members. Although the canonical Notch3
transcript was elevated (2- to 5-fold) in Notch1/Ikzf1+/ and
Ikzf1DN/+ leukemic cells, expression of alternative transcripts
from the Notch3 locus was not detected (Figure S2D).
Utilization of Notch1 Alternative TSSs during T Cell
Development and Leukemogenesis
During T cell development, activation of Notch signaling mani-
fests during the DN3 to DP transition, where it contributes to
proliferation of immature thymocytes (Figure 4A) (von Boehmer,
2009). Notch transcriptional targets, such as Hes1, Il2ra, andImmunity 33, 685–Notch1 itself, are greatly induced during this
phase. We examined the activity of canonical
and alternative Notch1 promoters at these
stages by testing for promoter-specific tran-
scripts. E1c- and E1a-E3-containing Notch1
transcripts were expressed at DN3 but progres-
sively declined at the DN4 and DP stages,
similar to Hes1 and other Notch signaling tran-
scriptional targets (Figures 4B and 4C). Thus,
induction of canonical and 50-alternativeNotch1
promoters is part of the Notch transcriptional
response at the DN3 stage of T cell differentia-
tion. Quantitative RT-PCR revealed higher
expression of E1a-E3 containing transcripts
than E1c transcripts at DN3 (Figure 4B and Fig-
ure S3A). However, at the DP stage, expression
of E1c transcripts was maintained at a higher
basal level (Figure 4B). RNA analysis of polyA+
RNA from DN thymocytes also indicated
elevated expression of E1a transcripts at this
stage (Figure 4D) but did not detect the intra-
genic transcripts, and further analysis by RT-
PCR was not possible because of interference
from presplicing mRNA (data not shown).Activation of alternative Notch1 transcripts was next exam-
ined during leukemogenesis in Ikaros mutant thymocytes.
Three major stages have been defined that demarcate the tran-
sition from a pretransformed to a transformed state and are
common to thymocytes with distinct Ikaros mutations (Fig-
ure 4A and Figure S3B). Nonetheless, the rate at which different
mutant cells undergo this process varies inversely with the
levels of residual Ikaros and family members. The first stage
is defined by Ikaros mutant thymocytes, which like WT thymo-
cytes consist predominantly of DP with low expression of TCR
(SI-DP TCRlo). Thymocytes from Ikzf1/ mice at 2–3 weeks,
Ikzf1DN/+ at <2 months, and Ikzf1+/ at <6 months are frequently
classified as SI. The second stage is defined by an aberrant
increase of cells with intermediate to high expression of TCR
and a variable DP-transitional phenotype (SII- TCRint-hi
CD4+CD8+ and CD4lo CD8+ and/or CD4+CD8lo). The third stage
is also categorized by a predominant TCRint-hi DP-transitional698, November 24, 2010 ª2010 Elsevier Inc. 689
Figure 4. Expression of Notch1 Transcripts during T Cell Development and Leukemogenesis
(A) Notch signaling during T cell development and stages of Ikaros-mediated leukemogenesis. Expression and signaling of canonical and alternative Notch1 iso-
forms is depicted during T cell development (DN3-SP) and leukemogenesis (stages I–III).
(B and C) Quantitative (B) and semiquantitative (C) RT-PCR with sorted DN3, DN4, and DP subsets from WT thymus and Ikzf1 mutant clones at stages I and III.
Expression of Notch1 exon1 (E1c), exon1a (E1a) and Hes1 transcripts was determined in (B) and (C).
(D and E) RNA (D) and protein (E) analysis of Notch1 transcripts and ICN during Ikaros-mediated leukemogenesis (SI–SIII). The arrow in (D) marks the E1a tran-
script and the star marks nonspecific hybridization. Lane 2 fromWT DN thymocytes was loaded with30% of the amount of RNA compared to lane 1 (WTDP).
(F) Quantitative RT-PCR analysis of E1a and E1c Notch1 transcripts in Ikzf1 mutant DP thymocytes at stages I, II, and III.
(G) Quantitative RT-PCR analysis of total Notch1 (exons 33–34) in Rbpj/Ikzf1DN/+ DP thymocytes.
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Ikaros-Dependent Epigenetic Regulation of Notch1population (frequently CD4lo CD8+) but with a progressive
increase in Notch1 signaling evident from accumulation of
ICN and increased levels of its transcriptional targets (SIII
early-late TCRint-hi ICNlo-hi, CD25lo-hi, Hes1neg-hi) (Figures 4A,
4C, and 4E and Figure S3B). Notably, clonality among the690 Immunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc.expanding TCRint-hi mutant thymocytes was detected both
before and upon Notch activation (Figure S3C, SI–SIII). Thus
clonal expansions can be initiated in the absence of Notch
signaling; however, the aggressive leukemic clones predomi-
nant at late stages are mostly Notch dependent.
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Ikaros-Dependent Epigenetic Regulation of Notch1Quantitative RT-PCR and RNA analysis of Ikaros mutant
thymocytes detected modest elevation of the 50 canonical and
alternative Notch1 transcripts by SII (Figures 4D–4F; E1c and
E1a; 2- to 3-fold). By SIII, marked by ICN accumulation, E1a
and E1c transcripts were further induced (Figures 4D–4F, >10-
fold). The increase in basal transcription from Notch1 promoters
was also seen in Rbpj/Ikzf1DN/+ thymocytes, indicating that
this is a direct effect of Ikaros and not caused by Notch signaling
manifested in a minority of the population (Figure 4G). Activation
of the Notch1 intragenic promoters lagged behind the E1a and
E1c promoters, given that their corresponding transcripts were
first detected at low level in early SIII (Figure 4D, lane 6). These,
together with the full-length (i.e., E1c- and E1a-) transcripts, were
further induced upon ICN accumulation in late SIII leukemic
clones (Figure 4D, lane 7 and 4E, lanes 5–7 and 9).
Thus, the 50 alternative and canonical Notch1 promoters are
part of a regulatory mechanism operative during both develop-
ment and leukemogenesis. The increase in basal transcription
from the 50 promoters in the preleukemic state coincides with
reduced Ikaros activity. A further robust induction of both the
50 and the intragenic Notch1 alternative promoters is detected
at later leukemogenesis stages and coincides with ICN
accumulation.
Function of Proteins Encoded by Alternative Notch1
Transcripts
The structure and activity of proteins generated by the alterna-
tiveNotch1 transcripts was assessed in cell culture. The proteins
encoded by the canonical Notch1 transcript (E1c: exon 1–34),
the 50 alternative transcript (E1a-E3: exon 1a–3–34), and the
longest intragenic transcript (E25: exon 25–34) were expressed
from a construct in which the C terminus PEST domain was
either replaced by a 6-Myc tag (Figures 5A–5C; E1a-E3 6MT,
and E1c 6MT) or left intact (Figure 5D, E25 and E1c; and data
not shown for E1a-E3) (Kopan et al., 1996; Mizutani et al.,
2001). Notch1 ICN with an intact PEST domain served as a posi-
tive control (Figure S4, ICN) (Aster et al., 2000). Similar results
were obtained with these vectors in HEK293T (Figure 5) and
U2OS cells (data not shown). The low amount of ICN detected
upon expression of the canonical Notch1 transcript in
HEK293T indicated low amounts of either ligand-receptor
engagement or constitutive Noch1 S3 cleavage in these cells.
The E1a-E3 Notch1 transcript supported higher amounts of
ICN production, nuclear localization, and activation of the
RBP-Jk reporter than the canonical transcript, although both ex-
pressed recombinant Notch1 proteins at similar levels (Figures
5B and 5C and Figure S4). GSI treatment reduced the amounts
of proteins generated by the E1a-E3 transcript, indicating
dependence of Notch signaling on processing (Figure 5B). In
addition to Notch1 proprotein (yellow star), the E1a-E3 transcript
produced a cleaved isoform that migrated more quickly than the
constitutively furin-cleaved protein (S1, green arrow) produced
by the E1c transcript (Figures 5A and 5B and Figure S4). This
protein was specifically recognized by an antibody to the S2-
cleaved Notch1 (S2-Val1711, yellow arrow), normally induced
upon ligand binding to the receptor (van Tetering et al., 2009).
The apparently constitutive processing of the E1a-E3 protein
by S2 and S3 (Val1744, purple arrow) was verified by immuno-
blotting and immunofluorescence (Figures 5B and 5C). GSIIincreased the S2 product and decreased the S3 product, further
supporting constitutive S2 cleavage of this isoform (Figure 5B).
Consistent with its S2-S3 processing, the E1a-E3 isoform (but
not E1c), was frequently detected in nuclei (Figure 5C).
The E25 transcript generated a range of short proteins that
stimulate RBP-Jk reporter activity through ICN production (Fig-
ure 5D). GSI reduced reporter activation by these isoforms, indi-
cating that their activity is also dependent on S3 cleavage. None-
theless, unlike E1a-E3 there was no accumulation of an S2
product, indicating translation downstreamof this site (Figure 5D,
and data not shown). The six putative translation initiation methi-
onines in the E25 transcript were next evaluated by mutagenesis
(Figures 5A and 5E and Figure S5). Methionine to alanine substi-
tution at position 1727 (E25: M1727A) abolished the major
isoform (Figures 5E, red asterisk and Figure S5). Interestingly,
mutations of downstream methionines (M1796A, M1845A, and
M1848A; blue stars) increased translation from M1727 and
reporter activity, indicating that competition between alternative
translation sites may modulate Notch signaling driven by the
intragenic transcripts (Figure 5E, Figure S5, and data not shown).
The 50 and intragenic Notch1 promoters thus generate
stronger transcriptional activators than the canonical promoter.
In both cases this is due to the production of proteins whose
cleavage by ADAMs and/or g-secretase is either accelerated
or occurs constitutively when ligand is limiting.
The Role of Ikaros in Dictating Chromatin Accessibility
at the Notch1 Locus
Transcriptional output is partly determined by local enhancer
and promoter chromatin regions that control access to the basal
transcriptional machinery and regulators. We examined the
histone modifications H3K4me3, H3K27me3, H3K36me3, and
H3K9/14ac at the Notch1 locus in WT and Ikaros mutant
thymocytes at stage II (SII-DP TCRint-hi) prior to activation of
Notch signaling. Combinations of these modifications provide
a measure of transcriptionally active (H3K4me3, K9/K14ac,
and K36me3), poised (H3K4me3 and K9/K14ac; H3K4me3,
K9/K14ac, and K27me3; H3K4me3 and K27me3) and repressed
(H3K27me3) chromatin (Campos and Reinberg, 2009; Menden-
hall and Bernstein, 2008; Schones and Zhao, 2008). We used
chromatin immunoprecipitation coupled to high-throughput
sequencing (ChIP-Seq) to compare the chromatin status of
genes in total thymocytes mostly at the DP stage (85%) with
that of genes expressed in DN, DP, or SP populations. Enrich-
ment in H3K36me3, a chromatin marker of long-range transcrip-
tion elongation, was seen only in genes expressed in DP cells
(Figure S6).
Islands of H3K4me3 and H3K9/K14Ac are found primarily in
promoter regions and are in part generated by recruitment of
the transcription initiation complex (Guenther et al., 2007). In
WT DP, a major H3K4me3/H3K9/K14ac island was detected at
the canonical Notch1 promoter (Figure 6A). A minor island was
detected 13 kb upstream, spanning E1a and further validating
this region as an alternative 50 promoter (Figure 6A). No
H3K4me3 or H3K9/K14ac islands were detected in the Notch1
intragenic region in WT DP thymocytes. This indicates that the
intragenic promoters are neither active nor poised, consistent
with Notch1 transcript analysis at the DN and DP stages (Figures
4B–4D). H3K36me3 was detected downstream of the canonicalmmunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc. 691
Figure 5. Ligand-Independent Signaling Provided by Alternative Notch1 Isoforms
(A) Exon and protein domain composition of the canonical (E1c) and alternative Notch1 transcripts (E1a-E3 and E25, see also Figure S5). Notch1-translated iso-
forms are depicted with asterisks: black, 300 kDa canonical (E1c FL and 6MT); and orange, exon 1a (E1a-E3 6MT) proproteins; green, M1615; pink, M1659; red,
M1727; and blue, M1796, M1845, and M1848 and by processing with arrows: green, S1 site; yellow, S2 site; and purple, S3 site. The construct substituted the
PEST domain by a 6 MYC-tag is depicted 6MT and with the intact C terminus FL.
(B and C) The activity and cellular localization of the E1a-E3 transcript (E1a-E3 6MT) was compared to that of the canonical (E1c 6MT). Expression vectors were
cotransfected with the RBP-Jk pGALuc reporter into HEK293 cells and assayed for relative luciferase units (RLUs) (as light units measure in 10 s.) and recombi-
nant protein production by immunoblotting and immunofluorescence with antibodies to the c-Myc, the S2 (Val1711), and S3 (Val1744) epitopes as well as to a C-
terminal domain. Notch1 proteins are demarcated by asterisks as in (A). A representative experiment out of three is shown.
(D) Notch1 protein production and activity was also assessed in the presence (+) or absence () of GSI. The proteins generated by the alternative E25 transcript
were tested for activity relative to the E1c FL. Reporter activity and protein analysis were performed as in (B).
(E) Mutational analysis mapped a major as well as minor translation sites within the E25 transcript. Expression studies were performed as in (B) and (D). Asterisks
indicate distinct translation products as in (A). All experiments were repeated at least three times. SDs are shown as error bars.
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Figure 6. Loss of Ikaros Binding to Notch1 Locus Affects the Notch1 Chromatin Environment
Peaks are shown for ChIP-Seq performed with anti-H3K27me3 (red), anti-H3K4me3 (blue), anti-H3K9/14ac (orange), anti-H3K36me3 (green), anti-Ikaros (purple
and light blue), and anti-ICN (dark red). The Notch1 canonical promoter (black arrow), 50 alternative promoter (green arrow), and intragenic alternative promoters
(red arrows) are identified.
(A) Histone modification status and Ikaros binding at Notch1 locus in WT DP thymocytes. Islands of H3K4me3 and H3K9/14ac (black vertical arrows) decorated
the transcriptionally active E1c promoter and poised E1a promoter.Notch1 expression in DP thymocyteswas confirmed by the H3K36me3 elongationmark. High
confidence (purple, p value 105), and lower confidence (light blue, p value 103) Ikaros-binding sites were identified at the promoters and at intragenic locations
and validated by ChIP-PCR. An asterisk marks the internal control in duplex ChIP-PCR.
(B) Histone modification status at the Notch1 locus in Ikaros null SII thymocytes that have not activated Notch signaling.
(C) A direct comparison (equal tag numbers) of histone modifications at the E1c and E1a promoters. IkBS relative to methylation and acetylation islands are also
indicated.
(D) Notch1 ICN binding at Notch1 at late stage III of leukemogenesis. Binding of ICN was examined by ChIP-Seq and candidate ChIP at four Ikaros binding sites,
at intron 15 (negative control) and at the Hes1 promoter (positive control). These experiments were repeated twice with similar results.
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short-term to long-term elongation (Joshi and Struhl, 2005).
H3K27me3, which marks a restrictive chromatin state, was not
detected at the Notch1 locus (data not shown).
ChIP-Seq for Ikaros identified two high-confidence Ikaros-
binding sites (IkBS) (p value 105) 10 kb upstream and down-
stream of the canonical TSS (Figure 6A; IkBSN1 and IkBSN4,
purple). The upstream Ikaros site is within 3 kb of the E1a
promoter. Notably, both sites are in minor H3K4me3 islands.
Four lower-confidence IkBS (p value 103) were also found:
one at the E1c promoter, two at the intron 2 and one at the
E25 promoter (Figure 6A, IkBSN2, IkBSN3, IKBSN4 and IkBSN5,
blue). ChIP-PCR validated the high-confidence Ikaros sites as
well as two of the lower confidence sites (IkBSN2 and IkBSN5).
We next analyzed the chromatin status of the Notch1 locus in
Ikzf1/ preleukemic thymocytes before activation of Notch
signaling (Figure 6B, stage II: ICN). Cell staging was validated
by testing for H3 modifications at Notch1 targets such as Hes1
and Il2ra. Both genes lacked the elongation marker H3K36me3
(Figure 6B). Furthermore, Hes1 retained H3K27me3 and
H3K4me3 throughout the locus, consistent with a bivalent and
repressed state in DP cells. In contrast, the Notch1 locus dis-
played an increase in H3K4me3 and H3K9/K14ac islands span-
ning the 50 canonical (E1c) and the alternative (E1a) promoters
(Figures 6B and 6C). Increased intensity and range of
H3K36me3 was also seen, consistent with the increase in basal
transcription from the E1c and E1a promoters in SII mutant
thymocytes. In addition to the increase in H3K4me3 and H3K9/
K14ac at the 50end of Notch1, a group of de novo H3K4me3
and H3K9/K14ac islands was detected at the intragenic region,
starting at E25 and extending into the 30 end (Figure 6B). These
H3K4me3 and H3K9/K14ac islands encompass the intragenic
promoter region that is activated upon ICN accumulation at SIII
of leukemogenesis. These data highlight that the genomically
intact Notch1 locus acquires a more permissive chromatin
configuration at its canonical and alternative promoters before
their robust induction by ICN.
Given reports that Ikaros and ICNwork through the same DNA
sequences (Beverly and Capobianco, 2003), we examined the
distribution of ICN at the IkBS of Notch1 in SIII leukemic cells
by ChIP-PCR (Figure 6D). Strong ICN enrichment was detected
at IkBSN1 but not at downstream sites (Figure 6D). As previously
reported, ICNwas highly enriched at theHes1 promoter. Binding
of ICN at IkBSN1 was confirmed by ChIP-Seq, which also re-
vealed a striking distribution within the intragenic methylation
and acetylation islands starting downstream of IkBSN5 in E25
(Figure 6D).
These epigenetic studies provide insight into the transcrip-
tional regulation of Notch1 promoters in WT, preleukemic, and
leukemic thymocytes and establish a direct role for Ikaros in re-
stricting chromatin accessibility at these regulatory sites.
Further Delineation of Notch1 Regulatory Regions
Reveals E2A as a Contributing Factor
The Notch1 promoter regions and Ikaros binding sites were next
evaluated in silico for cis-element composition (Figure 7). A large
CpG island surrounded E1c, as is typical of 50%–70% of
mammalian promoters (Sandelin et al., 2007). Coincident with
the CpG island was an array of GC boxes, which can bind the694 Immunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc.transcriptional activator Sp1. The 50 alternative promoter E1a
did not have these elements, suggesting it is normally weak
and may need recruitment of additional factors for activation
(Figure 7A). Strong cross-species conservation was detected
for the E1a promoter region, supporting its functional importance
(data not shown). A set of classic promoter elements is found in
the intragenic region, particularly upstream of E28. This intra-
genic TSS contains a CpG island and TATA, CCAAT, and GC
boxes at appropriate upstream distances, indicating a capacity
for strong transcription when this region is accessible (Figure 7A,
lower panel). This is consistent with the evidence that binding of
Ikaros and possibly other factors is necessary to restrict access
to this site.
Sequence analysis identified many potential transcription
factor binding sites, including several clusters of E2A motifs
within or near IkBS sites (Figure 7A). One site is directly upstream
of the canonical promoter close to IkBSN2, two are just down-
stream of the canonical CpG island and one is within IkBSN4,
the IkBS 10 kb downstream from the promoter (not shown).
Several E2A sites are located directly upstream of the TSS in
E1a. In the region of the intragenic promoters, a cluster of E2A
sites extends downstream of IkBSN5 in E25 into E26, another
cluster is found in intron 26, and another is found in intron 29.
Given the abundance of E2A sites and their proximity to Notch1
regulatory regions, we examined Notch1 promoter use in E2A
deficient (Tcf3/) primary leukemic clones and cell lines with
active Notch signaling (Figure 7B and Figure S7) (Reschly
et al., 2006). Alternative Notch1 transcripts predominated in
these clones, indicating that Ikaros and E2A participate in
a common mechanism of leukemic transformation. E2A binding
to multiple regulatory elements in the Notch1 locus, especially
sites at the deleted canonical Notch1 promoter region, provide
a plausible explanation of the acceleration of leukemogenesis
upon Notch1 promoter deletion in Ikaros mutant thymocytes.
DISCUSSION
Here, we showed that the Notch1 locus is regulated by a combi-
nation of transcriptional promoters and enhancers supporting
a feed-forward loop that probably augments Notch signaling at
appropriate stages of T cell differentiation and leukemic transfor-
mation. Ikaros is one of the key regulators in this processworking
at the epigenetic level to limit recruitment of transcription-related
factors.
The presence of alternative promoters at theNotch1 locuswas
first revealed by studies in leukemic cells from mice with
combinedmutations in Ikzf1 and theNotch1 canonical promoter.
Although activity of the alternative Notch1 promoters was
augmented in the Notch1/Ikzf1+/ leukemic cells, it was also
elevated in other leukemiamodels in which the canonicalNotch1
promoter was intact. Nonetheless, combined deletion of the
Notch1 canonical promoter and Ikzf1 accelerated this process,
indicating participation of additional negative regulatory factors
acting through the deleted region. A likely candidate is E2A
because it binds at the canonical Notch1 promoter (Yashiro-Oh-
tani et al., 2009) and has similar effects as Ikaros on Notch1 tran-
scriptional regulation and leukemogenesis. These studies also
show that in T cells, theNotch1 exon1 deletion is not a null allele,
particularly under conditions in which active Ikaros repression is
Figure 7. Ikaros and E2A Coregulate Canonical and Alternative Notch1 Promoters
(A) Sequence analysis of the canonical and alternative promoter regions identified four promoter elements—CpG islands and TATA, CCAAT, and GC boxes—and
binding sites for E2Awithin or near regions of Ikaros binding. IkBSs sites are purple or light blue. Promoter elements and putative E2A sites are represented in blue
(+ strand) or red ( strand).
(B)Notch1 alternative transcripts and ICN protein were detected in Tcf3/ leukemic cells. Exons in the vicinity of transcription start sites and 30 UTR are indicated
with gray boxes. The table summarizes the usage of each TSS and 30 UTRs.
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other contexts, it will be important to assess whether deletion of
negative regulatory elements and de-repression of these ligand-
independent isoforms occurs in other cell types.
In addition to the canonical promoter, two alternative Notch1
promoter regions were mapped at the 50 and at an intragenic
location. Transcriptional analysis of the Notch1 locus during
normal T cell development indicated that at the DN3 stage,
both the 50 alternative and canonical promoters were active,
whereas at the DP stage, only the canonical promoter retained
activity. Epigenetic studies in DP thymocytes confirmed the
presence of permissive chromatin at the active promoter but
also indicated that the inactive 50 alternative promoter was in
a permissive chromatin configuration possibly poised for future
transcriptional induction upon activation of Notch signaling. In
contrast to the 50 promoters, the intragenic promoter region
was transcriptionally repressed through the DN3-to-DP transi-
tion, was not marked for transcriptional activation at the chro-
matin level, and displayed extensive Ikaros binding.
During loss of Ikaros-mediated leukemogenesis, all three sets
of Notch1 promoters acquired more permissive chromatin prior
to activation of Notch signaling. Increase in permissive chro-
matin was detected at the 50 alternative and canonical promoters
and most notably at the intragenic promoters in preleukemic
thymocytes on an intactNotch1 locus. The increase in chromatinIaccessibility at the 50 Notch1 promoters correlated with an
increase in basal transcription detected at the preleukemic state
that preceded the strong transcriptional induction detected upon
ICN accumulation at the leukemic state. Importantly, inhibition of
Notch signaling, through g-secretase inhibition or by Rbpj inac-
tivation, interfered with the robust transcriptional induction at
both the canonical and alternative promoters in leukemic cells
but did not alter the increase in basal transcription observed in
preleukemic thymocytes.
Both alternative promoters were responsible for the produc-
tion of proteins that signal in limiting ligand. The full-length
Notch1 protein generated by the E1a promoter lacks the signal
peptide present in the canonical unprocessed form and appears
to be processed differently. Notably, it is constitutively cleaved
by ADAM metalloproteinases (S2) and g-secretase (S3) in
limiting ligand conditions. Thus, alternative 50 promoter and
exon usage may dictate an alternative route of cell trafficking
and receptor processing that enhances Notch signaling that is
pending further investigation. A range of short Notch1 protein
isoforms was produced by the intragenic promoter region. A
major isoform was translated from a site downstream of the S2
or ADAM site that lacked the ligand binding and NRR domains
andwas a potent activator of the Notch transcriptional response.
Given these data we propose the presence of a feedback loop
in Notch signaling supported by a network of epigenetic andmmunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc. 695
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ligand dependence for activity. Local chromatin at the Notch1
locus controls access to the basal transcription machinery and
to enhancer proteins that regulate this process. The presence
of Ikaros at binding sites located in proximity to all three Notch1
promoters is responsible for restricting chromatin. Ikaros associ-
ation with negative chromatin-remodeling factors such as Mi-2b
and HDACs may restrict access or activity of positive chromatin
regulators such as MLL and HATs also recruited to these sites
(Kim et al., 1999; Sridharan and Smale, 2007). Loss of Ikaros
relieves chromatin restriction, increasing access to the basal
transcription machinery at both ligand-dependent and -indepen-
dentNotch1 promoters. This precipitates a forbidden increase in
ICN, which even if present at low amounts is more effectively re-
cruited to its target sites that are more accessible because of
Ikaros removal. ICN is a potent transcriptional enhancer that
can function from at least two regions in the Notch1 locus. One
is at the promoter-distal IkBSN1, and the second is at an
extended region downstream of the IkBSN5 in E25. Importantly,
this ICN-binding region shows extensive overlap with the de
novo intragenic islands of permissive chromatin arising in Ikaros
mutant preleukemic cells. Interactions of ICN with HATs
(Wallberg et al., 2002) at its target sites may further impact
transcription initiation. Transcription of the Notch1 locus is prob-
ably affected by a number of regulatory factors. In addition to
Ikaros and E2A, our preliminary studies indicate a similar aber-
rant activation of alternative Notch1 promoters in abnormally
expanding DP in an activated Akt2 transgenic model (data not
shown) (Malstrom et al., 2001). Thus, both nuclear and signaling
factors implicated in leukemogenesis may participate in the
regulation of this feed-forward loop in Notch signaling.
Stage-specific activation of theNotch1 promoters may be one
key for modulating levels of Notch signaling during development
and leukemogenesis. The induction of promoters expressing
isoforms with differential ligand requirement may support
a feed-forward mechanism that augments Notch signaling
required for expansion of immature thymocytes. At the DN3
stage, this may be jump-started by the ligand-dependent canon-
ical Notch1 E1c isoform and propagated by the more active E1a
isoform. Subsequently at the DP stage, the E1a promoter is
repressed and only the canonical promoter remains modestly
active. Together with limited ligand availability, this may restrict
Notch signaling to levels supporting cell survival and not prolifer-
ation at this stage of differentiation (Laky and Fowlkes, 2008). In
the Notch1-deficient cells, deletion of the canonical promoter
and lack of expression of the ligand-dependent Notch1 isoform
prevented activation of the 50 alternative promoter under condi-
tions of restrictive chromatin. However, upon loss of Ikaros (and
possibly E2A), aberrant increase in chromatin accessibility
augments basal transcription at the alternative Notch1
promoters, marking transition to a preleukemic state. This allows
a progressive increase in ICN accumulation that eventually
causes robust induction of both ligand-dependent and -inde-
pendent Notch1 promoters, thus sealing the transition to the
leukemic state. Aberrant activation of the Notch1 promoters
collaborates with Notch1 mutations that target the PEST domain
in the mouse genetic systems studied here to exacerbate the
leukemia phenotype. It will be important to determine whether
such a mechanism is also manifested in human leukemia in696 Immunity 33, 685–698, November 24, 2010 ª2010 Elsevier Inc.which a predominance of mutations in the heterodimerization
and PEST domains has been described. Strong cross-species
conservation of both the canonical and alternative promoters
gives support. Targeting the transcriptional regulation of Notch1
may open new avenues for leukemia treatment. Small molecules
targeting enzymes that control chromatin accessibility in combi-
nation with g-secretase inhibitors may provide better treatment
protocols for curing T-ALL.
EXPERIMENTAL PROCEDURES
Mice
Ikzf1/, Ikzf1DN/+ (Georgopoulos et al., 1994), Notch1fl/fl (Radtke et al., 1999),
and Rbpjfl/fl mice (Radtke et al., 1999; Tanigaki et al., 2002; Wang et al., 1996)
were bred and housed under pathogen-free conditions. The Notch1 and RBP-
Jk deficient strains were maintained as intercrosses to either lck-Cre or hCD2-
Cre (de Boer et al., 2003; Lee et al., 2001).
Cell Culture and Proliferation Assays
Notch1/Ikzf1+/ and other mutant cell lines established from primary thymic
lymphomas were maintained in RPMI media as described in the Supplemental
Information.
Flow Cytometry
Phenotypic analysis of thymocytes and splenocytes was performed by flow
cytometry with FACSCanto (BD) or MoFlo (Cytomation). Data were analyzed
with the FloJo software (Tristar). The antibodies used in this study were
CD4-PE-Cy5.5 (or CD4-PE-Cy7), CD8a-APC-Cy7, TCRb-APC, CD5-PE,
CD25-PE (or CD25-APC-Cy7), HSA-PE, CD69PE, Thy1.2-PE, CD62L-APC,
and CD44-APC as previously described (Williams et al., 2004).
D-J Rearrangement and Notch1 and Rbpj Deletion Analyses
TCRb D-J rearrangement as well as deletion at the Notch1 and Rbpj loci were
examined by genomic PCR as previously described (Winandy et al., 1995).
RT-PCR, Rapid Amplification of 50 End of cDNAs and RNA Analysis
The cDNA was synthesized from RNA with SuperScriptII RTase (Invitrogen).
For qRT-PCR, transcripts were amplified with HotStart-IT SYBER Green
qPCR Master mix (USB) on the ABI sequence detection system (Applied Bio-
systems). All qRT-PCR reactions were performed in triplicate.
For rapid amplification of 50 end of cDNAs (RACE), the first strand cDNAwas
synthesized with 1 mg polyA+-selected RNA using the SMARTER RACE cDNA
Amplification kit (CLONTEC) according to the manufacturer’s instructions. For
Northern analysis, standard protocols were used.
Immunoblotting and Immunofluorescence Studies
The antibodies used for these studies were anti-Notch1, anti-c-Myc (9E10)
(Santa Cruz), anti-cleaved Notch1 (S2, Val1711) (van Tetering et al., 2009),
anti-Cleaved Notch1 (S3, Val1744) (Cell Signaling Technology, anti-PSF
(B92) (Sigma), or anti-Mi-2b (Williams et al., 2004). For immunofluorescence
(IF), cells were grown and transfected with the indicated plasmids on chamber
slides. Forty-eight hours after transfection, cells were fixed with 4% PFA and
processed for IF as previously described (Go´mez-del Arco et al., 2005).
Images were taken with a Nikon A1R confocal microscope.
Chromatin Immunoprecipitation and ChIP-Sequencing
Ikaros chromatin immunoprecipitation (ChIP) was performed as described
previously (Harker et al., 2002) with some modifications. The following anti-
bodies were used to study histone modifications: anti-H3K4me3 (Abcam
ab8580 or Millipore 07-473), anti-H3K9/K14Ac (Millipore 06-599), anti-
H3K27me3 (Millipore 07-449), and anti-H3K36me3 (abcam ab9050). For
ChIP-sequencing, chromatin from 2 3 107 to 2 3 108 cells was used per IP.
Precipitated DNA and an equivalent amount of whole genomic DNA were
amplified with the DNA Sample Prep Kit (Illumina or New England Biolabs).
Amplified samples were run on the Genome Analyzer at Systems Biology
Lab, Harvard University. Image analysis and base calling were performed
Immunity
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assembly was conducted with ELAND software. Antibody-enriched regions
and signal peaks were identified by MACS algorithm with input as control
(Zhang et al., 2008). For data visualization, properly shifted tags were counted
along the chromosome, and tag counts in wiggle format were uploaded into
Affymetrix IGB.
Expression and Reporter Assays
The following vectors were used for expression and reporter activity studies:
(1) pGALuc, a Notch activity reporter plasmid with six tandem RBP-J binding
sites driving Luciferase expression was kindly provided by A. Ferrando
(Columbia University, NY) with permission of T. Honjo (Mizutani et al., 2001).
(2) pCS2-E1c (mNotch1-canonical full-length Notch1) and pCS2-E1c 6MT
(canonical full-length Notch1 with 6 tandem myc-tag epitopes inserted after
amino acid 2183 at the C-terminal part of the protein) were kindly provided
by R. Kopan (Kopan et al., 1996). (3) MIG andMIG ICN retroviruses were kindly
provided by M. Toribio and W. Pear (Aster et al., 2000). (4) MIG E1c. The E1c
cDNA was cloned from the pCS2 vector into the MIG RI vector. (5) MIG E1a,
PCS2 E1a and PSC2 E1a 6MT. Notch1 cDNA with the alternative E1a-E3 50
end was cloned into MIG RI, pCS2 and pCS2 6MT. (6) MIG E25 Notch1. A
cDNA representative of the intragenic transcript spanning exon 25 through
exon 34 was cloned into the MIG RI retrovirus.
The Notch1 expression plasmids were cotransfected in HEK293 or U2 OS
cells, together with the RBP-J Luciferase-reporter pGALuc, and 24 hr later
cells were harvested for luciferase and protein analysis.
Primers
All primers used for RT-PCR, 50 RACE, probe generation, and candidate ChIP
are listed in Table S1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
doi:10.1016/j.immuni.2010.11.008.
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